Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical

MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings